


PATENT
Docket No. 11746/46004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor : **ROTHMAN, et al.**
Serial No. : **10/053,520**
Filing Date : **February 17, 2002**
For: **HEAT SHOCK PROTEIN-BASED VACCINES
AND IMMUNOTHERAPIES**
Examiner : **To Be Assigned**
Art Unit : **1646**

Commissioner for Patents
Washington D.C. 20231
BOX SEQUENCE

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner for Patents, Washington, D.C. 20231 on
September 25, 2002


Lawrence P. Casson (Reg. No. 46,606)

**SUBMISSION OF
SEQUENCE LISTING STATEMENTS**

SIR:

**STATEMENT UNDER 37 CFR §1.825(a) THAT REVISED "SEQUENCE
LISTING" CONTAINS NO NEW MATTER**

The sequences set forth in the computer readable and written "Sequence Listing" are identical with those in the originally filed application. No new matter has been added.

SEQ ID NOS:1-320 of the accompanying "Sequence Listing" are identical to those listed in the "Sequence Listing" that is part of the originally filed application. SEQ ID NO:321 represents the conjugate peptide OVA-BiP that is set forth in the originally filed specification at page 72 at the end of the paragraph that begins with "Peptides."

The format of the accompanying sequence listing conforms to the revised rules effective July 1, 1998. The parent application and original sequence listing were filed prior to that date.

Accordingly, required fields relating to sequence sources and features (e.g., fields with identifiers <220>, <221>, <222> and <223>) have been introduced. Data in certain General Information fields have been updated. The "Sequence Listing" is believed to conform to all formal requirements.


STATEMENT UNDER 37 CFR §1.821(f) and 37 CFR §1.821(g)
THAT REVISED "SEQUENCE LISTING" AND
COMPUTER READABLE COPY ARE THE SAME

As required by 37 CFR §1.821(f), Applicants state that the information recorded in computer readable form submitted herewith in accordance with 37 CFR § 1.821(e) is identical to the written revised "Sequence Listing."

Respectfully submitted,
KENYON & KENYON

Dated: September 25, 2002

By:



Lawrence P. Casson
Reg. No. 46,606

One Broadway
New York, NY 10004
Direct Dial: 212-908-6204
Fax: 212-425-5288